Have a personal or library account? Click to login
Influence of Process Parameters on Content Uniformity of a Low Dose Active Pharmaceutical Ingredient in a Tablet Formulation According to GMP Cover

Influence of Process Parameters on Content Uniformity of a Low Dose Active Pharmaceutical Ingredient in a Tablet Formulation According to GMP

Acta Pharmaceutica
Volume 64 (2014): Issue 3 (September 2014)
By: Jan Muselík,  Aleš Franc,  Petr Doležel,  Roman Goněc,  Anna Krondlová and  Ivana Lukášová  
Open Access
|Oct 2014

References

  1. 1. L. M. Vercaigni and G. G. Zhanel, Clinical significance of bioequivalence and interchangeability of narrow therapeutic range drugs: Focus on warfarins, J. Pharm. PharmSci. 1 (1998) 92-94.
    Search in Google Scholar
  2. 2. A. K. Wittkowsky, Generic warfarin: Implications for patient care, Pharmacotherapy 17 (1997) 640-643; DOI: 10.1002/j.1875-9114.1997.tb03741.x.
    Search in Google Scholar
  3. 3. A. Jaffer and L. Bragg, Practical tips for Warfarin dosing and monitoring, Clev. Clin. J. Med. 70 (2003) 361-371; DOI: 10.3949/ccjm.70.4.361.10.3949/ccjm.70.4.361
    Search in Google Scholar
  4. 4. United States Court of Appeals, Third Circuit. Court decision in re: Warfarin sodium antitrust litigation, 391 F.3d 516, December 2004; https://bulk.resource.org/courts.gov/c/F3/391/391.F3d.516.02-3758.02-3757.02-3755.02-3603.html; access date October 15, 2013.
    Search in Google Scholar
  5. 5. H. Halkin, A. Shapiro, D. Kurnik, R. Loebstein, V. Shalev and E. Kokia, Increased warfarin doses and decreased international normalized ratio response after nationwide generic switching, Clin. Pharmacol. Ther. 74 (2003) 215-221; DOI: 10.1016/S0009-9236(03)00166-8.10.1016/S0009-9236(03)00166-8
    Search in Google Scholar
  6. 6. C. N. Swenson and G. Fundak, Observational cohort study of switching warfarin sodium products in a managed care organization, Am. J. Health-Syst. Pharm. 57 (2000) 452-455.10.1093/ajhp/57.5.452
    Search in Google Scholar
  7. 7. A. E. Sawoniak, A. F. Shalansky, P. J. Zed and R. Sundreji, Formulary considerations related to warfarin interchangeability, Can. J. Hosp. Pharm. 55 (2002) 215-218.
    Search in Google Scholar
  8. 8. A. Franc, B. Žaludek, R. Goněc, M. Maleček, H. Tkadlečková and A. Petrovičová, Method of Producing Dosage Units of a Solid Drug Form Containing Warfarin Sodium Salts as Active Component, WO Pat. 2005034919 17 October 2003.
    Search in Google Scholar
  9. 9. A. Franc, M. Rabišková and R. Gonĕc, Impregnation: a progressive method in the production of solid dosage forms with low content of poorly soluble drugs, Eur. J. Parent Pharm. Sci. 16 (2011) 85-93.
    Search in Google Scholar
  10. 10. L. Z. Benet and J. E. Goyan, Bioequivalence and narrow therapeutic index drug, Pharmacotherapy 15 (1995) 433-440; DOI: 10.1002/j.1875-9114.1995.tb04379.x.
    Search in Google Scholar
  11. 11. The »Barr Laboratories« Court decision, United States District Court for the District of New Jersey, Civil action No. 92-1744, January 2004; http://www.navigategmp.com/pdf/BarrLabs.pdf; access date October 19, 2013.
    Search in Google Scholar
  12. 12. J. Berman, D. E. Elinski, C. R. Gonzales, J. D. Hofer, P. J. Jimenez, J. A. Planchard, R. J. Tlachac and P. F. Vogel, Blend uniformity analysis: Validation and in-process testing. Technical Report No. 25. PDA (Parenteral Drug Association), PDA J. Pharm. Sci. Technol. 51 (1997) S1-99.
    Search in Google Scholar
  13. 13. FDA Guidance for industry, ANDAs: Blend Uniformity Analysis, Draft guidance, August 1999; http://www.fda.gov/OHRMS/DOCKETS/98fr/992635gd.pdf; access date October 19, 2013.
    Search in Google Scholar
  14. 14. FDA Guidance for industry, Powder Blends and Finished Dosage Units - Stratified In-process Dosage Unit Sampling and Assessment, Draft guidance, October 2003; http://www.fda.gov/OHRMS/DOCKETS/98fr/03d-0493-gdl0001.pdf; access date October 19, 2013.
    Search in Google Scholar
  15. 15. FDA Guidance for industry, Powder Blends and Finished Dosage Units - In-process Bend and Dosage Unit Inspection (Sampling and Evaluation) for Content Uniformity, Revised draft guidance, January 2004; http://www.fda.gov/ohrms/dockets/dailys/04/jan04/013004/03D-0493_emc-000003-01.pdf; access date October 19, 2013.
    Search in Google Scholar
  16. 16. FDA reference material, Oral Solid Dosage Forms Pre/post Approval Issues (1/94), Guide to inspections of oral solid dosage forms, pre/post approval issues for development and validation, January 1994. http://www.fda.gov/ICECI/Inspections/InspectionGuides/ucm074928.htm; access date 19 October, 2013.
    Search in Google Scholar
  17. 17. P. Cholayudth, Establishing acceptance limits for probability of passing multiple stage tests in process validation through a process capability approach, J. Valid. Tech. 15 (2009) 77-90.
    Search in Google Scholar
  18. 18. J. S. Bergum and H. Li, Acceptance limits for the new ICH USP 29 content-uniformity test, Pharm. Tech. 31 (2007) 90-100.
    Search in Google Scholar
  19. 19. J. Kushner, Incorporating Turbula mixers into a blending scale-up model for evaluating the effect of magnesium stearate on tablet tensile strength and bulk specific volume, Int. J. Pharm. 429 (2012) 1-11; DOI: 10.1016/j.ijpharm.2012.02.040.10.1016/j.ijpharm.2012.02.040
    Search in Google Scholar
  20. 20. J. Zheng, Formulation and Analytical Development for Low-Dose Oral Drug Products, John Wiley & Sons, New Jersey 2009, pp. 169-196.10.1002/9780470386361
    Search in Google Scholar
  21. 21. J. Hilden, M. Schrad, J. Kuehne-Willmore and J. Sloan, A first-principles model for prediction of product dose uniformity based on drug substance particle size distribution, J. Pharm. Sci. 101 (2012) 2364-2371; DOI: 10.1002/jps.23130.10.1002/jps.23130
    Search in Google Scholar
  22. 22. Y. Pu, M. Mazumder and C. Cooney, Effects of electrostatic charging on pharmaceutical powder blending homogeneity, J. Pharm. Sci. 98 (2009) 2412-2421; DOI: 10.1002/jps.21595.10.1002/jps.21595
    Search in Google Scholar
  23. 23. J. Muselík and A. Franc, Evaluation of content uniformity of tablets with a low content of the active ingredient with a narrow therapeutic index, Ces. Slov. Farm. 61 (2012) 271-275.
    Search in Google Scholar
  24. 24. D. M. Taylor, Measuring techniques for electrostatistics, Electrostatics 51-52 (2001) 502-508.10.1016/S0304-3886(01)00107-3
    Search in Google Scholar
  25. 25. H. Martens and M. Martens, Modified jack-knife estimation of parameter uncertainty in bilinear modeling by partial least squares regression (PLSR), Food Qual. Prefer. 11 (2000) 5-16; DOI: http://dx.doi.org/10.1016/S0950-3293(99)00039-7.10.1016/S0950-3293(99)00039-7
    Search in Google Scholar
  26. 26. A. Franc, J. Muselík, R. Máslová and J. Hadrabová, Content uniformity of warfarin-containing mixtures and tablets, Ces. Slov. Farm. 62 (2013) 177-181.
    Search in Google Scholar
  27. 27. M. Perrault, F. Bertrand and J. Chaouki, An investigation of magnesium stearate mixing in a Vblender through gamma-ray detection, Powder Technol. 200 (2010) 234-245.10.1016/j.powtec.2010.02.030
    Search in Google Scholar
  28. 28. H. Yang, How many batches are needed for process validation under the new FDA Guidance?, PDA J. Pharm. Sci. Technol. 67 (2013) 53-62; DOI: 10.5731/pdajpst.2013.00902.10.5731/pdajpst.2013.0090223385564
    Search in Google Scholar
  29. 29. Camo software website, Classical DoE methods and PLS-ANOVA, Specific methods for analyzing designed data; http://www.camo.com/resources/classical-doe-methods-pls-anova.html; access date October 19, 2013.
    Search in Google Scholar
  30. 30. Camo software. User’s manual to Unscrambler X software, v.1.3.
    Search in Google Scholar
DOI: https://doi.org/10.2478/acph-2014-0022 | Journal eISSN: 1846-9558 | Journal ISSN: 1330-0075
Journal RSS Feed
Language: English
Page range: 355 - 367
Accepted on: Apr 2, 2014
Published on: Oct 8, 2014
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
content uniformity,
warfarin,
validation,
narrow therapeutic index,
Faraday pail,
PLS regression
Related subjects:
Pharmacy,
Pharmacy, other

© 2014 Jan Muselík, Aleš Franc, Petr Doležel, Roman Goněc, Anna Krondlová, Ivana Lukášová, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Previous articleVolume 64 (2014): Issue 3 (September 2014)Next article